Cabozantinib and Avelumab Treatment Combination Safe and Effective for Metastatic Kidney Cancer

The treatment combination of cabozantinib and avelumab appears safe and effective in patients with metastatic clear cell renal cell carcinoma (mccRCC), according to a study presented at the 2022 International Kidney Cancer Symposium: North America.

Haoran Li, MD, PhD, and colleagues assessed 12 patients with newly diagnosed mccRCC. The population of interest was administered cabozantinib 20 mg (n=3), 40 mg (n=3), and 60 mg (n=6) plus avelumab (10 mg/kg q2weeks). The primary outcomes of interest were defined as safety and identification of the recommended phase 2 dose. The secondary outcomes of interest included objective response rate and radiographic progression-free survival (PFS).

According to the results, the International mRCC Database Consortium scores were 4 (favorable), 6 (intermediate), and 2 (poor). The investigators noted that dose-limiting toxicities were not observed in any study cohort. Overall, a clinical benefit (complete response plus partial response plus stable disease) was observed in 92% of the patients. PFS rate was noted in 67.7% and 33.5% of patients, respectively, at 6 and 12 months.

“Cabozantinib/avelumab in mccRCC is safe and preliminarily efficacious,” the researchers concluded.

Source: Li H, Sahu K, Swami U, et al. Phase 1 trial of combination therapy with avelumab and cabozantinib in patients with newly diagnosed metastatic clear cell renal cell carcinoma. Poster 40. Presented at the 2022 IKCS: North America; November 4-5, 2022; Austin, Texas.ro